December 18, 2006 -- BioSante won appoval for Bio-E-Gel, an estradiol gel for hot flashes; Exelixis and Bristol-Myers Squibb will collaborate to develop targeted therapies for cancer; Somaxon released positive data from a Phase III trial of its sedative, Silenor; ZymoGenetics filed for approval of its recombinant human thrombin; Lilly upped its bid for Icos from $32 to $34; VaxGen said the FDA will maintain its clinical hold on the company’s anthrax vaccine; Biomet accepted a $44 per share bid from private equity investors; and Vertex said GlaxoSmithKline will stop developing an experimental preotease inhibitor for AIDS. The Centient Biotech 200™ fell 14 points to 3950, a drop of .36%. More details...
